International Cancer Institute

Cancer Care, Research Training & Education

Home CLP Lung Cancer Preceptorship

ICI LUNG CANCER PRECEPTORSHIP

Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Lung Cancer patients in sub-Saharan Africa.

Eldoret, Kenya

 

Training Duration:  6 weeks

Course Director: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist Executive

Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com Website: www.intercancer.com

 

Course Coordination: Dr. Kevin Makori

Head, Office of Education and Training

International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email:  kevin.makori@intercancer.com Website: www.intercancer.com

 

This educational activity is provided independently by International Cancer Institute (ICI)

ICI Education & Training Mission Statement

 

The ICI Preceptorship Program Mission is to measurably contribute to cancer patients’ safety and health outcomes and to support practice improvement by providing CME/CPD activities that enhance the ability of physicians and other healthcare team members to deliver quality and optimal healthcare services.

 

Purpose

The purpose of the ICI Preceptorship Program is to develop educational activities that clearly link the needs of the learner/participants with the planning process, format, and delivery of each activity, resulting in high-quality continuing medical education/continued Professional Development opportunities that will increase the knowledge, competence, and performance of health-care providers.

 

Content Areas

 

The ICI Preceptorship Program activities include practical, evidence-based, best clinical practice information for a broad variety of common oncology and hematology conditions, innovations in primary and specialty patient care in NCDs, new procedural training, and specialty fora. The appropriate content for each course is determined based on the results of a practice gap analysis relative to the target audience’s scope of practice, as well as the identified expected outcomes. Content is free of commercial bias.

 

General Target Audience: ICI Preceptorship/CME/CPD activities focus on the needs of generalist and specialist physicians and other multidisciplinary healthcare team members at ICI-affiliated cancer centers nationally and in sub-Saharan Africa as appropriate.

 

Type of Activities Provided by ICI

 

In order to accomplish our educational goals, ICI CME uses a range of activity formats based on the content and desired results of the activity. Current offerings include live and video conferenced activities, live regularly scheduled series, internet CME activities, enduring materials, and hands-on skills workshops. ICI also jointly sponsors activities with regional specialty societies, non-profit educational organizations, and government agencies when mutually desired goals and outcomes are best achieved by such relationships.

 

Expected Results of the Preceptorship Program

 

ICI Preceptorship/CME/CPD is committed to assessing the impact and effectiveness of its CME/CPD Program. ICI courses are designed to: increase knowledge of new treatments, diagnostic tools, and procedures; improve compliance with the specific evidence-based standard of care protocols; improve competence, performance, and/or patient outcomes; and promote efficient use of resources. We employ assessment methods to evaluate the extent to which our activities result in changes in knowledge, competence, and performance. CME activities in conjunction with quality improvement projects have measurable outcomes to report. An emphasis during the planning process is placed on intended learning and desired change in knowledge, competence, and performance. The ICI Education and Training Office works in collaboration with other departments/offices of the International Cancer Institute and its partners who are involved and interested in quality improvement processes and patient safety.

 

Target Audience

 

The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; urologists; other health care professionals (internists, primary care physicians, pathologists, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants and nurse practitioners) involved and/or interested in the therapeutic management of patients with prostate cancer.

 

Statement of Need

 

New developments in lung cancer treatment are often not widely disseminated, especially in sub-Saharan Africa, resulting in patients not receiving the best or most up-to-date care. Health care providers need current information on all factors related to lung cancer treatment, including screening, diagnosing, surgical and non-surgical strategies, and overall management of patients with lung cancer. Successful lung cancer treatment requires complex strategies and it may be difficult for clinicians to select from the various options available for diagnosis and treatment. Opportunities to discuss cases and compare treatment plans with colleagues are necessary for physicians to optimize their care plans through multidisciplinary tumor boards. ICI continues to conduct at least two virtual multidisciplinary tumor boards weekly. This course will augment that educational activity.

 

LEARNING OBJECTIVES

 

At the end of this educational activity, participants should be able:

  1. To learn about lung cancer data in Kenya and sub-Saharan Africa (SSA)
  2. To learn about the evidence-base for lung cancer screening
  3. To understand diagnostic modalities including the role of Biopsies / Re-Biopsies / Liquid Biopsy in Patients with NSCLC
  4. To learn about the TNM staging and the different subtypes of NSCLC
  5. To understand the different treatment strategies in NSCLC
  6. To learn about the management of early stage Non-Small-Cell Lung Cancer and use of adjuvant treatments
  7. To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
  8. To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC (Personalized Therapies)
  9. To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
  10. To learn about the systemic treatment of mesothelioma and SCLC
  11. To learn about the role of supportive and palliative care for lung cancer

Disclosure of Conflicts of Interest

 

International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

 

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

 

Disclaimer

 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Disclosure of Unlabeled Use

 

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Method of Participation and Request for Credit

 

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures, and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

 

The Program

 

LECTURES/COURSEWORK

 

Orientation to the course 

  1. Lung Cancer Data in Kenya and SSA
  2. Lung Cancer Prevention, Screening and Early detection
  3. Lung Cancer Diagnostics & Pathology
  4. NSCLC staging and Treatment
  5. SCLC staging and Treatment 
  6. Role of surgery in management of Lung Cancer 
  7. Role of Radiotherapy in management of lung cancer 
  8. Mesothelioma 
  9. Lung Cancer Bench to Bedside: Now and Future Personalized therapies 
  10. Supportive and Palliative care in Lung Cancer 

 

CLP 100: ICI Lung Cancer Preceptorship Course Schedule

 

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours)

 

All those interested in registration to this course, please send your information to info@intercancer.com

CLP104 Lung Cancer Preceptorship

KSh2,000.00KSh20,000.00

SKU: N/A Category: Tag:

Description

Subscribing to the course

You can purchase the entire course at Ksh. 20,000 ($20) or units you are interested in at Ksh. 2,000 ($20) per unit.

  1. Orientation to the course
  2. Lung Cancer Data in Kenya and SSA
  3. Lung Cancer Prevention, Screening and Early detection
  4. Lung Cancer Diagnostics & Pathology
  5. Role of Imaging in Lung Cancer Management
  6. NSCLC staging and Treatment
  7. SCLC staging and Treatment
  8. Role of surgery in the management of Lung Cancer
  9. Role of Radiotherapy in the management of lung cancer
  10. Mesothelioma
  11. Lung Cancer Bench to Bedside: Now and Future Personalized therapies
  12. Supportive and Palliative care in Lung Cancer
  13. Biosimilars in Lung cancer Management
  14. Research priorities & Clinical Trial Opportunities in Lung Cancer in SSA

Additional information

CLP

Lung Cancer Data in Kenya and SSA, Lung Cancer Prevention, Screening and Early detection, Lung Cancer Diagnostics & Pathology, Role of Imaging in Lung Cancer Management, NSCLC staging and Treatment, SCLC staging and Treatment, Role of surgery in the management of Lung Cancer, Role of Radiotherapy in the management of lung cancer, Mesothelioma, Lung Cancer Bench to Bedside: Now and Future Personalized therapies, Supportive and Palliative care in Lung Cancer, Biosimilars in Lung cancer Management, Research priorities & Clinical Trial Opportunities in Lung Cancer in SSA, Full course

International Cancer Institute